Attend three 2-hour sessions held over two consecutive days

Neurofibromatosis

The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques

ACT Workshop

National Institutes of Health Clinical Center, 9000 Rockville Pike

Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain

Acceptance and Commitment Therapy for Adolescents and Adults With Neurofibromatosis Type 1 and Chronic Pain: A Pilot Study

National Cancer Institute (NCI)

Subjects will receive lapatinib for 10 days prior to surgery for vestibular schwannoma resection.

Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection.

Subjects received lapatinib for 1500 mg by mouth daily for 10 days prior to surgery for vestibular schwannoma resection

Lapatinib

Control subjects did not receive any intervention prior to surgery for vestibular schwannoma resection

Control

Total

Sex: Female, Male

Region of Enrollment

KPS is a physician-reported outcome measuring an individual's functional impairment. Scores range from 0% (death) to 100% (normal no complaints; no evidence of disease).
Specific to these results, 70% represents an ability to care for self; unable to carry on normal activity or to do active work, and 90% represents an ability to carry on normal activity; minor signs or symptoms of disease.

Karnofsky Performance Status (KPS)

Patients with a diagnosis of NF2

Steady-state plasma concentrations of lapatinib (ng/mL) at time of surgery, 10-13 days from starting drug.

Subjects received lapatinib 1500 mg by mouth for 10 days prior to surgery for vestibular schwannoma resection

Median Steady-state Lapatinib Plasma Concentrations at the Time of Surgical Resection

Count of tissue samples with lapatinib concentration >3uM

Subjects will receive lapatinib for 10 days prior to surgery for vestibular schwannoma resection.
lapatinib: 1500 mg lapatinib by mouth per day for 10 days

To Assess Whether Lapatinib Can Reach a Minimum Tumor Concentration Level of >3uM in VS After Oral Dosing.

Assessed number of samples with high expression of phospho-ErbB2 in tissue at time of surgery

Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection. Control subjects donate tissue at the time of surgery.

Assess the Level of ErbB2 Phosphorylation in VS.

Assess Markers of Tumor Proliferation and Cell Death in VS After Exposure to Lapatinib.

A comparison in the median lapatinib concentration (ng/g) in vestibular schwannomas associated with neurofibromatosis type 2 and sporadic vestibular schwannomas

Participants with vestibular schwannomas associated with a diagnosis of neurofibromatosis type 2

NF2 Associated VS

Participants with sporadic vestibular schwannomas (i.e. not associated with a diagnosis of neurofibromatosis type 2)

Sporadic VS

Explore the Difference in the Concentration of Lapatinib Achieved in NF2-related Versus Idiopathic VS.

Due to the sample sizes, a comparison between sporadic and NF2-related vestibular schwannomas could not be made. Instead we report the mutational status.

Seven participants had successful NF2 gene mutation analysis via exon scanning and MLPA.

Participants With Tissue Available for Gene Mutation Analysis

Perform NF2 Gene Mutation Analysis Via Exon Scanning and MLPA as Well as Protein Expression in All VS and Explore Differences Between Sporadic and NF2 Related VS.

Subjects received lapatinib 1500 mg by mouth for 10 days prior to surgery for vestibular schwannoma resection.

Control subjects did not receive any intervention prior to surgery for vestibular schwannoma resection.

Overall Study

Jaishri Blakeley

Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection. Control subjects donate tissue at the time of surgery. AEs were not collected in this group as there was no study intervention (i.e. they did not take the drug).

Vestibular Schwannoma

Neurofibromatosis 2

Acoustic Neuroma

Auditory Tumor

1500 mg lapatinib by mouth per day for 10 days

neurofibromatoses/päänsärky

Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain

Concentration and Activity of Lapatinib in Vestibular Schwannomas

Täydellisin lääketieteellinen tietokanta tieteen tukemana